Expanding reach from beyond Massachusetts to the nation’s capital to focus building on the surging government opportunities

LAWRENCE, MASSACHUSETTS, USA, December 5, 2017 /EINPresswire.com/ -- Rubix LS., a research and development engineering firm with a broad combination device platform in biotechnology today announced that the company has expanded to a new office location in the nation’s capital of Washington D.C.

This move comes at the heels of the news of the company moving toward Phase II clinical trials for Project Hercules, an orthopedic combination device targeting regenerative elements to restore bone, tissue and cellular health for those patients suffering from severing bone diseases and hip fractures. The company has created the office in Washington DC as the trajectory of the competencies the firm holds in the research and development discipline has started gain surging traction from the likes of the National Institute of Health (NIH), Food & Drug Administration (FDA), Department of Defense (DoD), National Aeronautics & Space Administration (NASA) and commercial entities that are currently conducting work under programs from federal agencies.

“We are excited that many of the pursuits and the hard work behind following up on these large scale opportunities are now coming to a fruition where it allowed us to expand. Having Rubix LS proven as a specialty R&D Engineering firm is surely resonating to the people who are now looking forward toward the future at these agencies. We’re happy to have a second home in Washington DC and look forward to further growth in many other cities to come” says Founder and CEO, Reginald Swift.

With already progressing with some work with the Defense Advanced Research Projects Agency (DARPA), a division within the DoD working on discrete and high-level technologies, this move provides a more concerted effort to push toward opening the platform, in which Rubix LS can expand their technical skillset and exposure to larger programs.

About Rubix LS:
Rubix LS., was founded in 2016 to merge advanced technologies in the life-science arena to advanced the therapy options for patients who are suffering from rare and orphan cancers and diseases. Rubix LS is developing combination devices, varied within different disciplines, that utilizes regenerative matrices developed from their nanotechnology methodology to combat ailments in multiple manners. Rubix LS is leveraging the nano-matrices and innovatively merging them into implantable devices that can intelligently target, destroy and grow cells for patients to combat highly resistant cancers that otherwise are difficult to treat from radiation and chemotherapy. You can find more on their website at www.rubixls.com.

Forward-Looking Statements
Some statements in this press release are not historical facts and constitute "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of the company's management. Forward-looking statements are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. The reader is cautioned not to rely on these forward-looking statements. The company does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Stacy Arrazcaeta
Rubix LS
978-655-6770
email us here